ProShares Ultra Bloomberg Natural Gas ETF vs Eli Lilly And Co — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $22.09, while Eli Lilly And Co trades at $1,149.25 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while ProShares Ultra Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals.
| BOIL | LLY | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $98.62 | $1.24K |
52-Week Low | $21.86 | $625.65 |
Market Cap | — | $1.03T |
Enterprise Value | — | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
BOIL trades at $21.86, down 3.62% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock recently underwent a 1:2 split on May 28, 2026. Natural gas market volatility dominates sentiment, with futures fluctuating based on weather forecasts and LNG demand. Fundamental data remains unavailable, highlighting the speculative nature of this leveraged ETF.
The outlook remains highly speculative given BOIL's leveraged structure and dependence on natural gas price movements. Key risks include contango erosion and weather-driven volatility. Investment opportunity exists for tactical traders betting on natural gas price surges, but long-term value erosion remains a significant concern for buy-and-hold investors.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Trailing returns across standard periods
Latest headlines on both assets
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →